Seeking Alpha
 

AMAG Pharmaceuticals, Inc. (AMAG)

- NASDAQ
  • Sep. 30, 2014, 12:45 PM
    | Comment!
  • Sep. 29, 2014, 4:27 PM
    • AMAG Pharmaceuticals (AMAG +28.2%) acquires privately-held Missouri-based Lumara Health for $675M in a cash-and-stock transaction. The deal consists of $600M in cash, $75M in stock and up to $350M in sales-related milestones.
    • Lumara focuses on women's health. It's lead product is the Orphan Drug Makena (hydroxyprogesterone caproate injection) indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past.
    • Also, Lumara divests its portfolio of OTC products to Perrigo for $82M.
    | Comment!
  • Sep. 29, 2014, 12:49 PM
    | Comment!
  • Sep. 29, 2014, 9:16 AM
    | Comment!
  • Feb. 7, 2014, 5:38 PM
    • Top gainers, as of 5:15 p.m.: EGOV +11.9%. RSTI +7.0%. THR +6.5%. TTMI +5.5%. VRSN +5.1%.
    • Top losers, as of 5:15 p.m.: LSCC -12.8%. RLD -10.6%. AT -5.5%. AMAG -5.3%. SEE -5.1%.
    | Comment!
  • Jan. 22, 2014, 10:40 AM
    • Remember, says analyst Carol Werther, AMAG has  $214M in cash and revenues of $80M in 2013. At $22 per share, enterprise value is $261M, or just over 3x revenue. The company was also cash flow positive the last two quarters. Her team would be aggressive buyers at $17.
    • The stock is now off 7.4% to $20.24.
    • Previous: AMAG gets a CRL from the FDA on Feraheme
    | Comment!
  • Jan. 22, 2014, 9:09 AM
    | Comment!
  • Jan. 9, 2014, 12:50 PM
    | 5 Comments
  • Dec. 31, 2013, 10:48 AM
    • AMAG Pharmaceuticals (AMAG +3.3%) is one of Summer Street's top picks for 2014.
    • Analyst Carol Werther likes the risk reward profile: "We see 20% downside contained risk (first time ever cash flow positive Q3 2013 and cash $213M) versus upside toward our price target on positive result from FDA and a sales re-acceleration gastroenterology specific launch plan to target the ~150 IBD centers."
    • Werther on Feraheme: "We assign a very high probability of January 2014 FDA approval."
    • Price target is $43, representing upside of ~87% from Monday's close.
    | Comment!
  • Sep. 25, 2013, 3:50 PM
    • AMAG Pharmaceuticals (AMAG -13.4%) slumps, falling double-digits on heavy volume.
    • In an SEC filing, the company says the FDA "has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments" for the company's iron deficiency anemia treatment Feraheme. (8-K)
    • It isn't entirely clear what this means, but investors should note that the company has a PDUFA date on October 21 for its sNDA.
    | Comment!
  • Sep. 25, 2013, 12:46 PM
    | Comment!
  • Jun. 10, 2013, 12:55 PM
    AMAG Pharmaceuticals (AMAG +2.2%) inks a licensing deal with Access Pharmaceuticals related to the commercialization of MuGard. a mucoadhesive that is designed to manage oral mucositis, in the US and its territories. Under the agreement, Access will receive an upfront licensing fee of $3.3M and a tiered, double digit royalty on net sales in the licensed territories. AMAG will also purchase existing MuGard inventory from Access.
    | Comment!
  • Jun. 7, 2013, 12:36 PM
    AMAG Pharmaceuticals (AMAG +3.4%) gains today after its European commercial partner, Takeda Pharmaceutical, submits a type-II variation to the European Medicines Agency for Rienso. The submission requests approval to expand beyond the current indication for the treatment of iron deficiency anemia in adult patients with chronic kidney disease, to include all adult patients who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used.
    | Comment!
  • May 22, 2013, 5:48 PM
    After-hours top gainers, as of 5:30 p.m.: PSUN +17.8%. HPQ +13.8%. NCS +7.6%. RTIX +5.8%. AMAG +5.6%.
    After-hours top losers: VICL -3.2%. CST -2.8%. SYPR -2.4%. HUM -1.8%. NG -1.8%.
    | Comment!
  • May 22, 2013, 12:52 PM
    Midday top 10 gainers: CLNT +125%. MBND +24%. ZLC +24%. RCON +22%. MNKD +15%. NOA +15%. INSM +15%. SGOC +19%. CETV +14%. SKS +14%.
    Midday top 10 Losers: STP -17%. LDK -14%. SWI -12%. MLP -11%. FXEN -12%. LAKE -10%. BALT -10%. DQ -10%. CSUN -9%. AMAG -9%.
    | Comment!
  • Apr. 23, 2013, 4:36 PM
    AMAG Pharma (AMAG): Q1 EPS of -$0.18 beats by $0.02. Revenue of $17.9M (+16% Y/Y) beats by $. Shares -3.5% AH. (PR)
    | Comment!
Visit Seeking Alpha's
AMAG vs. ETF Alternatives
Company Description
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous (IV) use; and MuGard, Mucoadhesive Oral Wound Rinse.